TY - JOUR
T1 - Cancer immunotherapy with CAR-T cells - Behold the future
AU - Graham, Charlotte
AU - Hewitson, Rebecca
AU - Pagliuca, Antonio
AU - Benjamin, Reuben
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Cellular therapy is a key tool to treat haematological malignancies. Over 40,000 allogeneic and autologous haematopoietic stem cell transplants (HSCTs) are performed annually across Europe.1 Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. Patients frequently require admission to intensive care, and management from a number of medical specialties. This exciting and powerful new therapy requires the formation of new multispecialty medical teams for safe delivery and to successfully manage the resultant complications.
AB - Cellular therapy is a key tool to treat haematological malignancies. Over 40,000 allogeneic and autologous haematopoietic stem cell transplants (HSCTs) are performed annually across Europe.1 Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. Patients frequently require admission to intensive care, and management from a number of medical specialties. This exciting and powerful new therapy requires the formation of new multispecialty medical teams for safe delivery and to successfully manage the resultant complications.
KW - Cancer immunotherapy
KW - CAR-T cell-related encephalopathy syndrome
KW - CAR-T cells
KW - Cellular therapy
KW - Cytokine release syndrome
UR - http://www.scopus.com/inward/record.url?scp=85051401334&partnerID=8YFLogxK
U2 - 10.7861/clinmedicine.18-4-324
DO - 10.7861/clinmedicine.18-4-324
M3 - Article
C2 - 30072559
AN - SCOPUS:85051401334
SN - 1470-2118
VL - 18
SP - 324
EP - 328
JO - Clinical Medicine, Journal of the Royal College of Physicians of London
JF - Clinical Medicine, Journal of the Royal College of Physicians of London
IS - 4
ER -
